Pregabalin Zentiva

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

pregabalín

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

Leyfilegt

Authorization date:

2015-07-17

Patient Information leaflet

                                48
B. FYLGISEÐILL
49
FYLGISEÐILL: UPPLÝSINGAR FYRIR NOTANDA LYFSINS
PREGABALIN ZENTIVA 25 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 50 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 75 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 100 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 150 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 200 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 225 MG HÖRÐ HYLKI
PREGABALIN ZENTIVA 300 MG HÖRÐ HYLKI
pregabalín
LESIÐ ALLAN FYLGISEÐILINN VANDLEGA ÁÐUR EN BYRJAÐ ER AÐ NOTA
LYFIÐ. Í HONUM ERU MIKILVÆGAR
UPPLÝSINGAR.
-
Geymið fylgiseðilinn. Nauðsynlegt getur verið að lesa hann
síðar.
-
Leitið til læknisins eða lyfjafræðings ef þörf er á frekari
upplýsingum.
-
Þessu lyfi hefur verið ávísað til persónulegra nota. Ekki má
gefa það öðrum. Það getur valdið
þeim skaða, jafnvel þótt um sömu sjúkdómseinkenni sé að
ræða.
-
Látið lækninn eða lyfjafræðing vita um allar aukaverkanir.
Þetta gildir einnig um aukaverkanir
sem ekki er minnst á í þessum fylgiseðli. Sjá kafla 4.
Í FYLGISEÐLINUM ERU EFTIRFARANDI KAFLAR:
1.
Upplýsingar um Pregabalin Zentiva og við hverju það er notað
2.
Áður en byrjað er að nota Pregabalin Zentiva
3.
Hvernig nota á Pregabalin Zentiva
4.
Hugsanlegar aukaverkanir
5.
Hvernig geyma á Pregabalin Zentiva
6.
Pakkningar og aðrar upplýsingar
1.
UPPLÝSINGAR UM PREGABALIN ZENTIVA OG VIÐ HVERJU ÞAÐ ER NOTAÐ
Pregabalin Zentiva tilheyrir flokki lyfja sem eru notuð við
meðferð á flogaveiki, taugaverkjum og
almennri kvíðaröskun hjá fullorðnum.
ÚTLÆGIR OG MIÐLÆGIR TAUGAVERKIR
Pregabalin Zentiva er notað til meðferðar á langvarandi verkjum af
völdum taugaskemmda. Fjöldi
mismunandi sjúkdóma getur valdið útlægum taugaverkjum, svo sem
sykursýki eða ristill.
Verkjatilfinningunni hefur verið lýst sem: hita, sviða, slætti,
skoti, sting, nístandi, krampa, verk, dofa,
tilfinningaleysi og náladofa. Skapbreytingar, svefntruflanir og
þreyta getur einnig fylgt útlægum og
miðlægum taugaverkjum og þeir geta haft áhrif á líkamlega og
f
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI LYFS
Pregabalin Zentiva 25 mg hörð hylki
Pregabalin Zentiva 50 mg hörð hylki
Pregabalin Zentiva 75 mg hörð hylki
Pregabalin Zentiva 100 mg hörð hylki
Pregabalin Zentiva 150 mg hörð hylki
Pregabalin Zentiva 200 mg hörð hylki
Pregabalin Zentiva 225 mg hörð hylki
Pregabalin Zentiva 300 mg hörð hylki
2.
INNIHALDSLÝSING
Pregabalin Zentiva 25 mg hörð hylki
Hvert hart hylki inniheldur 25 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 47,57 mg laktósaeinhýdrat.
Pregabalin Zentiva 50 mg hörð hylki
Hvert hart hylki inniheldur 50 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 5 mg laktósaeinhýdrat.
Pregabalin Zentiva 75 mg hörð hylki
Hvert hart hylki inniheldur 75 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 7,5 mg laktósaeinhýdrat.
Pregabalin Zentiva 100 mg hörð hylki
Hvert hart hylki inniheldur 100 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 10 mg laktósaeinhýdrat.
Pregabalin Zentiva 150 mg hörð hylki
Hvert hart hylki inniheldur 150 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 15 mg laktósaeinhýdrat.
Pregabalin Zentiva 200 mg hörð hylki
Hvert hart hylki inniheldur 200 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 20 mg laktósaeinhýdrat.
Pregabalin Zentiva 225 mg hörð hylki
Hvert hart hylki inniheldur 225 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 22,5 mg laktósaeinhýdrat.
3
Pregabalin Zentiva 300 mg hörð hylki
Hvert hart hylki inniheldur 300 mg pregabalín.
Hjálparefni með þekkta verkun
Hvert hart hylki inniheldur einnig 30 mg laktósaeinhýdrat.
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Hörð hylki.
Pregabalin Zentiva 25 mg hörð hylki
Ljósgrá hetta og ljósgrár bolur, hart gelatínuhylki u.þ.b. 15,9
mm að lengd með áletrunin
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 27-07-2015
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 27-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 19-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 27-07-2015

Search alerts related to this product